With the help of a €25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012.
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3% of the population of Western industrialised countries. The VIB spin-off, which has already raised €42m in a Series A financing round, is using its llama antibody (VHH) technology platform to produce the multispecific nanobody XVR012 and plans to advance a Phase I /II clinical study and submit a marketing authorisation application within one year. XVR012 is a single domain nanobody that, according to the EIBN, binds to different epitopes in the highly conserved S1 and S2 region of SARS-CoV-2. Previous work at the groups led at Professors Xavier Saelens and Nico Callewaert demonstrated that based on epitope sequencing, the potency is not expected to be impacted by the Delta, Alpha, Beta and Gamma variants of SARS-CoV-2.
In addition to developing XVR012, ExeVir also plans to expand its pipeline to other infectious diseases as part of its pandemic preparedness strategy. Antibodies against dengue fever are already in development.
In addition to the support of existing public institutional funds such as SFPI-FPIM (Société Fédérale de Participation et d‘Investissement), SRIW…
BioNTech SE and Ryvu Therapeutics S.A. announced that the companies have entered into a multi-target research collaboration targeting immune…
While the EU has already presented rules to establish a European Health Data Space (EHDS) and Europe’s Plan against Cancer within its Medicines…
The combination of Medsenic and Bone Therapeutics will expand Bone Therapeutics’ allogeneic cell therapy-based product portfolio in orthopedics…
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in…
In a proof-of-concept study, Doris Danninger and colleagues demonstrate that fungal mycelium skins can be grown and processed to serve as substrates…
Ethris GmbH a German company specialising in the development of mRNA vaccines, announced their collaboration with DIOSynVax Ltd., an English biotech…
Sino Biological and Ainnocence have joined forces to establish an AI-enabled platform for antibody affinity maturation.
SIGN UP FOR OUR FREE NEWSLETTER
© BIOCOM AG 2000 – 2023